Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Update

Sera Prognostics, Inc. (NASDAQ:SERA) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 844,400 shares, a decline of 19.6% from the December 31st total of 1,050,000 shares. Based on an average daily trading volume, of 102,700 shares, the short-interest ratio is presently 8.2 days. Approximately 4.0% of the shares of the stock are short sold.

Sera Prognostics Price Performance

Shares of SERA stock traded down $0.18 during trading hours on Friday, reaching $6.47. 112,445 shares of the company were exchanged, compared to its average volume of 92,625. Sera Prognostics has a fifty-two week low of $4.98 and a fifty-two week high of $12.35. The stock’s fifty day moving average is $7.36 and its two-hundred day moving average is $7.35. The company has a market cap of $218.49 million, a price-to-earnings ratio of -6.54 and a beta of 0.86.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same quarter last year, the firm earned ($0.23) EPS. On average, research analysts anticipate that Sera Prognostics will post -0.96 earnings per share for the current year.

Insider Buying and Selling at Sera Prognostics

In other news, General Counsel Benjamin Jackson sold 13,272 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $7.42, for a total transaction of $98,478.24. Following the transaction, the general counsel now directly owns 128,473 shares in the company, valued at approximately $953,269.66. This represents a 9.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joshua Phillips sold 12,163 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57. Following the transaction, the director now owns 2 shares in the company, valued at $12.78. The trade was a 99.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 93,215 shares of company stock worth $666,835 over the last ninety days. Corporate insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Sera Prognostics

Several large investors have recently bought and sold shares of the business. Jane Street Group LLC lifted its holdings in Sera Prognostics by 24.8% in the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after buying an additional 2,826 shares during the period. American Century Companies Inc. lifted its holdings in Sera Prognostics by 12.7% in the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after buying an additional 2,891 shares during the period. Rhumbline Advisers lifted its holdings in Sera Prognostics by 10.6% in the fourth quarter. Rhumbline Advisers now owns 36,101 shares of the company’s stock valued at $294,000 after buying an additional 3,468 shares during the period. Quest Partners LLC lifted its holdings in Sera Prognostics by 533.5% in the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after buying an additional 5,415 shares during the period. Finally, MetLife Investment Management LLC lifted its holdings in Sera Prognostics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock valued at $135,000 after buying an additional 9,722 shares during the period. 54.64% of the stock is currently owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.